Latest news with #Orbis'
Yahoo
6 days ago
- Health
- Yahoo
Orbis Medicines Accelerates Next-Generation Oral Macrocycle Platform with Enhanced Artificial Intelligence Capabilities of Gefion Supercomputer
Orbis begins using Gefion, Denmark's first AI supercomputer Composed of 1,528 NVIDIA H100 Tensor Core GPUs, system is optimized for large-scale, AI-driven projects Enables significant expansion of macrocycle chemical space exploration by Orbis' nGen platform New AI/ML capacity will leverage large proprietary datasets and generative AI to design novel orally available macrocycle alternatives to existing biologics COPENHAGEN, Denmark, June 03, 2025--(BUSINESS WIRE)--Orbis Medicines, a leader in oral macrocycle drug discovery, and the Danish Center for AI Innovation (DCAI) today announced that Orbis has begun using Denmark's first AI supercomputer, Gefion, which is owned and operated by DCAI. Gefion will allow the company to accelerate its mission of developing oral alternatives to widely used biologics and targeting important intra- and extracellular proteins that are currently difficult or impossible to drug with orally bioavailable compounds. Orbis is pioneering the systematic discovery and development of targeted, orally available macrocycles for diseases and targets traditionally treated with biologics. The company develops compounds known as nCycles, which can address a wide range of validated protein targets with unique oral bioavailability and membrane permeability features. "Our advanced nGen platform helps us quickly create large numbers of custom-designed macrocycles with unique properties and broad medical applicability," said Orbis CEO Morten Graugaard. "By combining this platform with Gefion's computing power, we can extend beyond the nearly 140 billion compounds in our existing libraries to design entirely new collections of these molecules. This means we can explore an even broader range of chemical possibilities and more fully unlock the potential of macrocycles to improve healthcare." "Orbis' nGen platform, which has already been used to design, synthesize and test more than 700,000 individual nCycles, is an ideal application for Gefion's capabilities," said Orbis Medicines Board Chair Mikael Dolsten, M.D., Ph.D. "Combining the power of this supercomputer with our in-house target nCycle data collection, generative AI, and nCycle synthesis capabilities will accelerate the development of orally available macrocycles that have the potential to disrupt the current biologics market and provide new treatment options for patients." "Gefion is designed to deliver AI innovation at scale through immense computing power applied to the most challenging problems," said Dr. Nadia Carlsten, CEO of DCAI. "As a biomedical start-up with its own internal AI technology applied to drug design and the ability to generate vast data sets, Orbis is an ideal partner to demonstrate what Gefion can unlock when matched with specialist expertise." DCAI's Gefion supercomputer contains 1,528 NVIDIA GPUs and is optimized for large-scale AI-driven projects. Gefion enables innovators to utilize advanced computation to accelerate discovery in various fields, including biotechnology and drug discovery. Gefion has previously been used by researchers, start-ups, and large enterprises to develop new AI models and perform simulations in weather modeling, quantum computing, and business automation. About Orbis Medicines Orbis Medicines is pioneering a new era for oral macrocycle drug discovery. Its nGen platform systematically delivers macrocycle candidates, termed nCycles. These are optimized for oral bioavailability, which has historically hindered therapeutic development of this versatile class of molecules. Orbis' pipeline is initially focused on nCycle candidates against targets validated by blockbuster biologic drugs delivered by injection. Proof-of-concept of Orbis' work has been published in Nature Communications and Nature Chemical Biology. The company has raised €116 million in venture funding to date, including a €90 million series A round led by NEA with new investors Lilly Ventures, Cormorant, EIFO and existing investors Forbion and Novo Holdings. Orbis is located in Copenhagen, Denmark and Lausanne, Switzerland. For more information, please visit: About nGen nGen is Orbis Medicines' technology platform for generating nCycles, a new class of fully synthetic macrocycle compounds optimized for oral bioavailability and membrane permeability. It consists of multiple proprietary integrated elements in a "lab in a loop" system starting with hit finding libraries of 100 billion compounds and target specific libraries designed by generative AI. The highly automated chemistry-based nGen platform can synthesize and screen up to 100,000 distinct synthetic macrocycles in weeks, allowing the company to discover candidates with the right properties to enable oral dosing and intracellular targeting. The scale and quality of the data produced from these real compounds, paired with machine learning and generative AI, creates an industry-leading platform that de-risks and accelerates development. About DCAI The Danish Centre for AI Innovation (DCAI) owns and operates Gefion, Denmark's flagship AI supercomputer, designed specifically for large-scale AI projects. Gefion ranks among the most powerful supercomputers globally powered by 1.528 NVIDIA H100 Tensor Core GPUs. DCAI's mission is to lower the barrier for accessing advanced computing capabilities, enabling customers to innovate and fostering ecosystem growth. DCAI customers include academic researchers, startups, government institutions, and enterprise customers doing large scale innovation. DCAI was formed as a company and funded by the Novo Nordisk Foundation and EIFO in 2024. View source version on Contacts Media: Matt CrensonTen Bridge Communications(917) 640-7930mcrenson@ General enquiries for DCAI & Gefion hello@ (+45) 35 27 66 00 Sign in to access your portfolio
Los Angeles Times
03-04-2025
- Business
- Los Angeles Times
Trump ordered to pay legal bill of UK firm he sued over Russia dossier
LONDON — A British judge on Thursday ordered U.S. President Trump to pay more than 625,000 pounds ($820,000) in legal costs to a company he unsuccessfully sued over a dossier alleging he took part in sex acts in Russia. Trump filed a claim in 2022 against Orbis Business Intelligence, a consulting firm founded by former British intelligence officer Christopher Steele. Steele was paid by Democrats to compile a 2016 dossier that contained rumors and uncorroborated allegations that caused a political storm just before Trump's first inauguration. It said that Trump had been 'compromised' by Russia's security service, and included two memos that claimed Trump had taken part in 'sex parties' in St. Petersburg and consorted with sex workers in Moscow. Trump denies all the allegations. His lawyers said the 'shocking and scandalous claims' were false and harmed his reputation. He sued the company, saying the dossier was phony and Orbis had violated British data protection laws. In a written witness statement, Trump said the allegations were 'wholly untrue.' Trump said he had not engaged in 'perverted sexual behavior including the hiring of prostitutes ... in the presidential suite of a hotel in Moscow,' taken part in 'sex parties' in St. Petersburg, bribed Russian officials, or provided them with 'sufficient material to blackmail me.' Judge Karen Steyn threw out the case in February 2024, without ruling on the truth of the allegations. She said the claim was 'bound to fail,' in part because Trump had waited several years to bring the action. Steyn ordered Trump to pay Orbis' costs, which lawyers for the president alleged had been set 'absolutely outrageously high.' After Trump failed to pay the first installment of 290,000 pounds, a hearing was held earlier this year without him to decide the full bill. Judge Jason Rowley said Thursday that the president must pay 626,058.98 pounds, with interest accruing daily at 12%.
Yahoo
03-04-2025
- Business
- Yahoo
Donald Trump must pay $821,000 legal bill over 'Steele dossier' lawsuit, UK court rules
LONDON (Reuters) -Donald Trump must pay over 626,000 pounds (about $821,500) in legal fees to a private investigations firm the U.S. president sued over a dossier which alleged ties between his 2016 election campaign and Russia, a London judge ruled on Thursday. Trump brought a data protection lawsuit against Orbis Business Intelligence over allegations in a dossier written by its co-founder, former British intelligence officer Christopher Steele, but Trump's claim was thrown out last year. The so-called Steele dossier alleged ties between Trump's 2016 election campaign and Russia as well as other salacious accusations, all of which Trump strenously denied. Trump had been ordered to make a payment of around 290,000 pounds towards Orbis' legal fees but failed to do so, Orbis' lawyers said at a previous hearing in January. This meant Trump was barred from being represented at a further hearing this week to consider Orbis' total legal bill and whether its costs were reasonable. Paul Arter, a costs lawyer for Orbis, said that Trump had very strong negotiating skills and was paying one of his own lawyers 750 pounds an hour. Arter said the case was very important to both parties, with Orbis having concerns about its survival should it lose, while Trump was seeking to protect his reputation. Faced with an opponent 'renowned as an aggressive litigator' who 'has a history of pursuing vendettas, certainly legally', it justified the rates Orbis were paying for their lawyers, Arter said. Judge Jason Rowley ruled that Trump owed Orbis 530,615 pounds, less than the more than 680,000 pounds Orbis had sought, but more than the 452,000 Orbis offered to accept. He also said Trump should pay another 95,000 pounds relating to the dispute over costs, making a total of just over 626,000 pounds. ($1 = 0.7621 pounds)
Reuters
03-04-2025
- Business
- Reuters
Donald Trump must pay $821,000 legal bill over 'Steele dossier' lawsuit, UK court rules
LONDON, April 3 (Reuters) - Donald Trump must pay over 626,000 pounds (about $821,500) in legal fees to a private investigations firm the U.S. president sued over a dossier which alleged ties between his 2016 election campaign and Russia, a London judge ruled on Thursday. Trump brought a data protection lawsuit against Orbis Business Intelligence over allegations in a dossier written by its co-founder, former British intelligence officer Christopher Steele, but Trump's claim was thrown out last year. The so-called Steele dossier alleged ties between Trump's 2016 election campaign and Russia as well as other salacious accusations, all of which Trump strenously denied. Trump had been ordered to make a payment of around 290,000 pounds towards Orbis' legal fees but failed to do so, Orbis' lawyers said at a previous hearing in January. This meant Trump was barred from being represented at a further hearing this week to consider Orbis' total legal bill and whether its costs were reasonable. Paul Arter, a costs lawyer for Orbis, said that Trump had very strong negotiating skills and was paying one of his own lawyers 750 pounds an hour. Arter said the case was very important to both parties, with Orbis having concerns about its survival should it lose, while Trump was seeking to protect his reputation. Faced with an opponent 'renowned as an aggressive litigator' who 'has a history of pursuing vendettas, certainly legally', it justified the rates Orbis were paying for their lawyers, Arter said. Judge Jason Rowley ruled that Trump owed Orbis 530,615 pounds, less than the more than 680,000 pounds Orbis had sought, but more than the 452,000 Orbis offered to accept. He also said Trump should pay another 95,000 pounds relating to the dispute over costs, making a total of just over 626,000 pounds. ($1 = 0.7621 pounds)
Associated Press
05-03-2025
- Health
- Associated Press
Orbis Medicines Names Veteran R&D Leader Mikael Dolsten Board Chair
Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the appointment of Mikael Dolsten, M.D., Ph.D., former Chief Scientific Officer, President, Pfizer Research & Development, as Chairperson of the Board of Directors. In more than 15 years at Pfizer, Dr. Dolsten oversaw the development and approval of more than 35 therapies and vaccines, and moved more than 100 drug candidates into clinical development. 'Mikael has a long and successful track record overseeing the development of blockbuster therapies and vaccines from discovery through approval, and shares Orbis' vision of embracing macrocycle-based medicines to unlock new treatment options for patients,' said Orbis Chief Executive Officer Morten Graugaard. 'Mikael's guidance will be pivotal as we advance our mission to provide novel, high-value oral alternatives to existing biologics, which have tremendous potential to address the needs of patients with chronic diseases and to streamline the healthcare system.' Prior to his tenure at Pfizer, Dr. Dolsten served in leadership roles at AstraZeneca, Boehringer Ingelheim, Pharmacia, and Wyeth Pharmaceuticals. Dr. Dolsten has served on several public boards in the US and Europe and has vast experience in business development, including 10 different mergers and acquisitions. 'By creating oral alternatives to biologics such as antibodies and peptides and designing oral drugs for hard-to-drug intracellular targets, the work Orbis Medicines is doing will dramatically expand access to treatment for patients suffering from many chronic and devastating diseases, which is truly the next frontier in drug discovery,' said Dr. Dolsten. 'What the Orbis Medicines team led by Morten are achieving in the field of oral macrocycle medicines positions the company to be a disruptor of the biologics market. I believe Orbis Medicines has the potential to become the leading oral macrocycles and oral biologics biotech company.' Dr. Dolsten's accomplishments include the introduction of a new class of oral medications for autoimmune diseases, the development and approval of targeted anaplastic lymphoma kinase (ALK) inhibitors in non-small cell lung cancer and Pfizer's rapid R&D response to the COVID-19 pandemic (see 'Note to Editors' below for more information). Orbis Medicines is pioneering the systematic discovery and development of targeted, orally available macrocycles for diseases and targets traditionally treated with biologics. Orbis develops compounds known as n Cycles, which can address a wide range of validated protein targets with unique oral bioavailability and membrane permeability features. About Orbis Medicines Orbis Medicines is pioneering a new era for oral macrocycle drug discovery. Its n Gen platform systematically delivers macrocycle candidates, termed n Cycles. These are optimized for oral bioavailability, which has historically hindered therapeutic development of this versatile class of molecules. Orbis' pipeline is initially focused on n Cycle candidates against targets validated by blockbuster biologic drugs delivered by injection. Proof-of-concept of Orbis' work has been published in Nature Communications and Nature Chemical Biology. The company has raised €116 million in venture funding to date, including a €90 million series A round led by NEA with new investors Lilly Ventures, Cormorant, EIFO and existing investors Forbion and Novo Holdings. Orbis is located in Copenhagen, Denmark and Lausanne, Switzerland. For more information, please visit: About n Gen n Gen is Orbis Medicines' technology platform for generating n Cycles, a new class of fully synthetic macrocycle compounds optimized for oral bioavailability and membrane permeability. It consists of multiple proprietary integrated elements in a 'lab in a loop' system starting with hit finding libraries of 100 billion compounds. The highly automated chemistry-based n Gen platform can synthesize and analyze up to 100,000 distinct synthetic macrocycles in weeks, allowing the company to discover candidates with the right properties to enable oral dosing and intracellular targeting. The scale and quality of the data produced from these real compounds, paired with machine learning, creates an industry-leading platform that de-risks and accelerates development. Note to Editors Notable accomplishments of Mikael Dolsten, M.D., Ph.D., during his tenure as Chief Scientific Officer, President, Pfizer Research & Development Introduced a new class of oral medications for autoimmune diseases dominated by biologics, including first-in-class JAK inhibitor Xeljanz (tofacitinib) for rheumatoid arthritis & ulcerative colitis, first-in-class Janus kinase 1 (JAK1) inhibitor Cibinqo (abrocitinib) for atopic dermatitis and the tyrosine kinase expressed in hepatocellular carcinoma/Janus kinase 3 (Tec/JAK3) drug Litfulo (ritlecitinib) for alopecia areata. Oversaw the development and approval of targeted ALK inhibitors in the highly competitive non-small cell lung cancer (NSCLC) market, including first-in-class ALK inhibitor Xalkori (crizotinib) and third-generation ALK inhibitor Lorbrena (lorlatinib). Other major drug approvals during Dr. Dolsten's tenure at Pfizer included the breast cancer drug Ibrance (palbociclib), the myeloma drug Elrexfio (elranatamab-bcmm), the poly (ADP-ribose) polymerase (PARP) inhibitor Talzenna, the vascular endothelial growth factor receptor (VEGFR) inhibitor Inlyta (axitinib), the oral anti-coagulant Eliquis (apixaban), the transthyretin amyloid stabilizing drug Vyndaqel (tafamadis), the Prevnar 20 vaccine and the RSV vaccine Abrysvo. Spearheaded Pfizer's rapid R&D response to the COVID-19 pandemic, receiving emergency use authorization and subsequently full approval for the oral antiviral therapy Paxlovid (nirmatrelvir/ritonavir) and for COVID-19 mRNA vaccine Comirnaty, in partnership with BioNTech. Dr. Dolsten announced his retirement from Pfizer in July 2024. SOURCE: Orbis Medicines Copyright Business Wire 2025. PUB: 03/05/2025 01:00 AM/DISC: 03/05/2025 12:59 AM
